-
Featured NewsWorld Sight Day 2022: Raising awareness on the importance of eye health -
Media ReleaseNovartis announces European Commission approval of Beovu® for people living with diabetic macular edema
-
Media ReleaseNovartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
-
Media ReleaseNovartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edema
-
Featured NewsWorld Sight Day 2021 -
Story
Restoring vision and hope to thousands in Southeast Asia -
Media ReleaseNovartis announces positive results from Phase III trials of Beovu® in diabetic macular edema, including dosing intervals up to 16 weeks
-
Media ReleaseNovartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können
-
Media ReleaseNovartis acquiert Arctos Medical, élargissant ainsi son portefeuille d’optogénétique afin de proposer des thérapies géniques aux patients souffrant d’une sévère perte de la vision
-
Media ReleaseNovartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss
-
Media ReleaseNew Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid
-
Media ReleaseResults from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020